Ultragenyx Pharmaceutical (NASDAQ:RARE) Issues Earnings Results

Ultragenyx Pharmaceutical (NASDAQ:RARE) issued its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($1.81) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.58), Zacks reports. Ultragenyx Pharmaceutical had a negative return on equity of 237.48% and a negative net margin of 87.34%. Ultragenyx Pharmaceutical updated its FY 2025 guidance to EPS.

Ultragenyx Pharmaceutical Stock Performance

RARE traded down $1.01 during midday trading on Tuesday, reaching $32.46. The company had a trading volume of 1,511,906 shares, compared to its average volume of 1,349,809. Ultragenyx Pharmaceutical has a 12-month low of $25.81 and a 12-month high of $53.47. The business has a 50-day moving average price of $31.35 and a two-hundred day moving average price of $32.93. The stock has a market cap of $3.13 billion, a PE ratio of -5.87 and a beta of 0.21.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. Morgan Stanley dropped their price objective on Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an “overweight” rating on the stock in a research note on Monday, July 14th. Weiss Ratings reissued a “sell (e+)” rating on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, October 8th. Wedbush reduced their price objective on shares of Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a “neutral” rating for the company in a research report on Monday, July 14th. Canaccord Genuity Group decreased their price objective on shares of Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a “buy” rating for the company in a research note on Friday, August 8th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $105.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Friday, September 5th. Ten research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Ultragenyx Pharmaceutical presently has an average rating of “Moderate Buy” and a consensus price target of $82.27.

Insider Activity at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 7,942 shares of the business’s stock in a transaction on Monday, October 13th. The stock was sold at an average price of $31.51, for a total value of $250,252.42. Following the sale, the chief financial officer directly owned 98,227 shares in the company, valued at $3,095,132.77. The trade was a 7.48% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Karah Herdman Parschauer sold 2,450 shares of the company’s stock in a transaction on Friday, September 12th. The shares were sold at an average price of $31.17, for a total value of $76,366.50. Following the transaction, the executive vice president directly owned 73,271 shares in the company, valued at $2,283,857.07. This represents a 3.24% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 10,456 shares of company stock valued at $328,486. 5.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Osaic Holdings Inc. boosted its position in Ultragenyx Pharmaceutical by 4,371.7% during the second quarter. Osaic Holdings Inc. now owns 4,740 shares of the biopharmaceutical company’s stock worth $172,000 after purchasing an additional 4,634 shares during the period. Headlands Technologies LLC grew its stake in Ultragenyx Pharmaceutical by 638.3% in the 2nd quarter. Headlands Technologies LLC now owns 11,983 shares of the biopharmaceutical company’s stock valued at $436,000 after buying an additional 10,360 shares in the last quarter. CANADA LIFE ASSURANCE Co raised its holdings in Ultragenyx Pharmaceutical by 12.5% during the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 26,398 shares of the biopharmaceutical company’s stock valued at $962,000 after acquiring an additional 2,937 shares during the period. E Fund Management Co. Ltd. raised its holdings in Ultragenyx Pharmaceutical by 9.1% during the 2nd quarter. E Fund Management Co. Ltd. now owns 9,052 shares of the biopharmaceutical company’s stock valued at $329,000 after acquiring an additional 752 shares during the period. Finally, Tidal Investments LLC lifted its position in shares of Ultragenyx Pharmaceutical by 4.7% during the second quarter. Tidal Investments LLC now owns 12,591 shares of the biopharmaceutical company’s stock worth $458,000 after acquiring an additional 564 shares in the last quarter. 97.67% of the stock is currently owned by institutional investors.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.